Pharmacyclics | Evaluate

December 06, 2016

Ash interview – Seattle’s aspirations versus big pharma’s appetites

October 26, 2016

Buy or build – big pharma’s freshness dilemma

September 07, 2016

How Gilead could go back to basics

August 23, 2016

Who’s next after Medivation?

August 22, 2016

Pfizer pays up

July 12, 2016

Who splashed the cash at the top of the market?

June 06, 2016

Asco 2016 – AbbVie pulls back rova-T curtain

May 23, 2016

In-house projects an ever-thinner slice of sales for big pharma

April 29, 2016

AbbVie caps week of cancer deals with huge Stemcentrx takeout

April 28, 2016

Sanofi’s desperation makes Medivation a must-have asset

April 22, 2016

AbbVie goes preclinical in pursuit of cancer payoff

Load More